Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study (Q39107868)

9 September 2017

title

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study (English)

1 reference

cost-effectiveness analysis

9 September 2017

main subject

1 reference

1

Mark Jit

1 reference

9 September 2017

Marc Brisson

2

1 reference

9 September 2017

Allison Portnoy

series ordinal

3

1 reference

9 September 2017

Raymond Hutubessy

series ordinal

4

1 reference

9 September 2017

publication date

9 June 2014

1 reference

9 September 2017

published in

The Lancet Global Health

1 reference

9 September 2017

volume

2

1 reference

9 September 2017

issue

7

1 reference

9 September 2017

page(s)

e406-14

1 reference

The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Economic evaluation of human papillomavirus vaccination in developed countries

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Modeling cervical cancer prevention in developed countries

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Carcinoma of the Cervix Uteri

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Human papillomavirus vaccine introduction--the first five years

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

The cost effectiveness of human papillomavirus vaccines: a systematic review

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Economic evaluation of human papilloma virus vaccination in the European Union: a critical review

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia

1 reference

https://api.crossref.org/works/10.1016/S2214-109X(14)70237-2

7 January 2021

10.1016/S2214-109X(14)70237-2

Identifiers

DOI

1 reference

9 September 2017

1 reference